17.38
-0.55 (-3.07%)
| Previous Close | 17.93 |
| Volume | 1,463,704 |
| Price / Sales | 3.03 |
| Price / Book | 2.93 |
| 52 Weeks Range |
| Profit Margin | -11.54% |
| Operating Margin (TTM) | -16.56% |
| Diluted EPS (TTM) | -0.610 |
| Quarterly Revenue Growth (YOY) | 7.50% |
| Total Debt/Equity (MRQ) | 68.08% |
| Current Ratio (MRQ) | 2.05 |
| Operating Cash Flow (TTM) | 7.61 M |
| Levered Free Cash Flow (TTM) | -2.21 M |
| Return on Assets (TTM) | -2.75% |
| Return on Equity (TTM) | -8.56% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Diagnostics & Research (US) | Mixed | Bullish |
| Diagnostics & Research (Global) | Mixed | Bullish | |
| Stock | NeoGenomics, Inc. | Mixed | Bullish |
AIStockmoo Score
| Analyst Consensus | 0.0 |
| Insider Activity | NA |
| Price Volatility | -5.0 |
| Technical Moving Averages | -2.5 |
| Technical Oscillators | -2.0 |
| Relative Valuation | NA |
| Financial Health | -1.3 |
| Macro Environment | -1.3 |
| AI Insight | NA |
| AI Technical | NA |
| Weighted Average | -2.08 |
Select this tab to load the latest available analysis.
|
NeoGenomics Inc provides oncology diagnostic testing and consultative services which include technical laboratory services and professional interpretation of laboratory test results by licensed physicians or molecular experts in pathology and oncology. It operates a network of cancer-focused testing laboratories in the United States and the United Kingdom. The company operates in a single segment and derives revenue from clients by providing clinical cancer testing, interpretation, and consultative services, molecular and NGS testing, comprehensive technical and professional services offerings, clinical trials and research, validation laboratory services, and oncology data solutions. |
|
| Sector | Healthcare |
| Industry | Diagnostics & Research |
| Investment Style | Small Growth |
| % Held by Insiders | 1.19% |
| % Held by Institutions | 98.21% |
No data within this time range.
No data within this time range.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |